Abstract
Purpose
Quality of life (QOL) should be improved during palliative chemotherapy for end-stage recurrent head and neck cancer. Therefore, we evaluated QOL in head and neck cancer patients during palliative chemotherapy with cisplatin and docetaxel.
Methods
Thirty patients were included in a prospective study between 2003 and 2007. Response, time-to-progression, overall survival, performance, and toxicity were estimated. QOL was assessed using the EORTC QLQ-C30 and the QLQ-H&N35 questionnaires at baseline, and after each chemotherapy cycle.
Results
The response rate was 17%. Sixty-three percent had stable disease. The median time-to-progression was 3.5 months. The median overall survival was 9.2 months. The QLQ-C30 score constipation and the QLQ-H&N35 scores swallowing, senses problems, speech problems, coughing, weight gain showed significant improvement.
Conclusions
Only some aspects of QOL are maintained or improved. The QLQ-H&N35 questionnaire seems to be more appropriate to measure QOL, but needs to be improved to account for the peculiarities of modern palliative chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bjordal K, De Graeff A, Fayers PM et al (2000) A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group. Eur J Cancer 36:1796–1807. doi:10.1016/S0959-8049(00)00186-6
Bjordal K, Ahlner-Elmqvist M, Hammerlid E et al (2001) A prospective study of quality of life in head and neck cancer patients. Part II. Longitudinal data. Laryngoscope 111:1440–1452. doi:10.1097/00005537-200108000-00022
Carvalho AL, Nishimoto IN, Califano JA et al (2005) Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 114:806–816. doi:10.1002/ijc.20740
Curran D, Aaronson N, Standaert B et al (2000) Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study. Eur J Cancer 36:834–844. doi:10.1016/S0959-8049(00)00056-3
Curran D, Giralt J, Harari PM et al (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25:2191–2197. doi:10.1200/JCO.2006.08.8005
Dreyfuss AI, Clark JR, Norris CM et al (1996) Docetaxel: an active drug for squamous cell carcinoma of the head and neck. J Clin Oncol 14:1672–1678
Ferrell B, Paice J, Koczywas M (2008) New standards and implications for improving the quality of supportive oncology practice. J Clin Oncol 26:3824–3831. doi:10.1200/JCO.2007.15.7552
Forastiere AA, Metch B, Schuller DE et al (1992) Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study. J Clin Oncol 10:1245–1251
Forastiere A, Koch W, Trotti A et al (2001a) Head and neck cancer. N Engl J Med 345:1890–1900. doi:10.1056/NEJMra001375
Forastiere AA, Leong T, Rowinsky E et al (2001b) Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393. J Clin Oncol 19:1088–1095
Gibson MK, Li Y, Murphy B et al (2005) Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. J Clin Oncol 23:3562–3567. doi:10.1200/JCO.2005.01.057
Glisson BS, Murphy BA, Frenette G et al (2002) Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck. J Clin Oncol 20:1593–1599. doi:10.1200/JCO.20.6.1593
Goldstein NE, Genden E, Morrison RS (2008) Palliative care for patients with head and neck cancer: “I would like a quick return to a normal lifestyle”. JAMA 299:1818–1825. doi:10.1001/jama.299.15.1818
Guntinas-Lichius O, Appenrodt S, Veelken F et al (2006) Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer. Laryngoscope 116:613–618. doi:10.1097/01.mlg.0000208366.34683.58
Karvonen-Gutierrez CA, Ronis DL, Fowler KE et al (2008) Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol 26:2754–2760. doi:10.1200/JCO.2007.12.9510
Nordgren M, Hammerlid E, Bjordal K et al (2008) Quality of life in oral carcinoma: a 5-year prospective study. Head Neck 30:461–470. doi:10.1002/hed.20735
Peters L, Sellick K (2006) Quality of life of cancer patients receiving inpatient and home-based palliative care. J Adv Nurs 53:524–533. doi:10.1111/j.1365-2648.2006.03754.x
Shin DB, Bang SM, Park SH et al (2008) Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors. Med Oncol 25:81–87. doi:10.1007/s12032-007-0045-5
Vermorken J, Hitt R, Geoffrois L et al (2007a) Cetuximab plus platinum-based therapy first-line in recurrent an/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): efficacy and safety results of a randomized phase III trial (EXTREME). Eur J Cancer Suppl 5:324
Vermorken J, Mesia R, Vega V et al (2007b) Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy—results of a randomized phase III (Extreme) study. In: 2007 annual ASCO meeting abtract No. 6091
Yeo W, Mo FK, Koh J et al (2006) Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol 17:1083–1089. doi:10.1093/annonc/mdl065
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Guntinas-Lichius, O., Rühlow, S., Veelken, F. et al. Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel. J Cancer Res Clin Oncol 135, 901–908 (2009). https://doi.org/10.1007/s00432-008-0525-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-008-0525-9